![\"EU](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/08\/shutterstock_1916217376.jpg\")
<\/p>\nThe European Commission hopes its planned legislation will enable biotechnology companies to bring products from laboratory to market more quickly.<\/p>\n
<\/p>\n
The European Commission is seeking help from the public to fine tune its plans to accelerate biotechnology products from lab to factory to market.<\/p>\n
The EU Biotech Act, which forms part of the Commission\u2019s broader Strategy for Life Sciences<\/a>, aims to improve the competitiveness of European biotech companies and ease their regulatory challenges.<\/p>\n A public consultation<\/a> on the proposed Act will run until 10 November 2025, after which its responses will feed into the EC\u2019s impact assessment of the legislative designs.<\/p>\n As the EC moves to improve the size and competitiveness of the EU\u2019s biotech sector it will assess the biotech plans in terms of:<\/p>\n Speed and streamlining<\/strong>: improving \u2018time-to-market\u2019, particularly for biotech start-ups, with a view to simplifying the regulatory environment. This also feeds into the Commission\u2019s existing work in areas such as the reform of pharmaceutical legislation<\/a>.<\/p>\n Financing<\/strong>: targeting access to new capital for companies at seed phase, as well as looking at how existing activities, incentives and funding schemes could be improved.<\/p>\n Biotechnology is going to be a key pillar to bring forward a completely new set of therapies, much more quickly available for the patients, but also a completely new way of innovation\u201d<\/p>\n Scale<\/strong>: helping the sector tap into the EU\u2019s existing infrastructure so that more development and production work can be carried out in the region. As part of this there could be support for new biotech clusters or centres of excellence, and biomanufacturing will be a particular focus.<\/p>\n